2007 Blogging Marketing San Diego 
Xconomy
MARCH 19, 2020
Many of our clients consider Hughes Marino the canary—an alert system that would be the first to go on record that the commercial real estate market had become toxic… like we did back in 1999 and 2007, Read more » Reprints | Share:
socalTECH
SEPTEMBER 20, 2010
Los Angeles-based Internet Brands , which operates a suite of online, advertising driven websites across a wide range of verticals, said Monday that it would go private in a $640M, private equity deal, bucking the trend of Southern California companies filing to get to the public markets. Internet Brands had gone public just three years ago.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Xconomy
SEPTEMBER 26, 2016
Tealium, a San-Diego startup that provides online advertising tag management and marketing services for enterprise customers, has raised $35 million in a growth financing deal intended to expand its technology and market reach. The company’s workforce has grown to about 270, including 80 in San Diego.
socalTECH
APRIL 14, 2011
He was also the founder of Wallstrip, which he sold to CBS back in 2007, is an investor in a significant number of web and social media companies. Howard is based in San Diego, and spoke to us about StockTwits. Howard Lindzon: StockTwits is a verticalized community for people to share stock ideas and market ideas, 24/7.
Xconomy
OCTOBER 5, 2016
San Diego-based Organovo (NASDAQ: ONVO ) said today it plans to use its 3D bio-printing technology to produce living human liver tissue “patches” that can be transplanted in patients with fatal liver disease. These initial areas encompass a $3 billion market opportunity, the company said. liver transplant waiting list.
Xconomy
JUNE 27, 2016
apiece, in post-market trading on Monday. Regulus was formed in September 2007 as a joint venture between Cambridge, MA-based Alnylam Pharmaceuticals (NASDAQ: ALNY ) and Carlsbad, CA-based Ionis Pharmaceuticals (NASDAQ: IONS ). Shares plummeted almost 60 percent, to $2.15 in November 2014.
Xconomy
NOVEMBER 1, 2016
For privately held biotechs, IPOs are the most common road to the public markets, but they’re not the only way. But they’re also much quicker and less costly to execute than IPOs, and are an alternative to traditional public offerings during a year in which the IPO market has been much more discerning of biotechs than in the recent past.
Expert insights. Personalized for you.
93 
Let's personalize your content